Definition

A preparation of autologous CD3+ CD4- CD8+ T cells targeting multiple human papilloma virus (HPV) tumor-associated antigens, including HPV types 16 and 18 antigens and survivin, with potential immunomodulating and antineoplastic activities. Following leukapheresis and ex vivo priming and expansion, the autologous HPV16/HPV18/survivin-specific CD8+ T cells NEXI-003 are re-introduced into the patient, where they target and kill tumor cells expressing these HPV tumor-associated antigens.